Abcam, ab248849, Anti-CYP7B1 antibody [EPR8395] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CYP7B1 antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8395,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248849 is the carrier-free version of
ab138497
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP7B1 also known as oxysterol 7-alpha-hydroxylase is a member of the cytochrome P450 superfamily of enzymes. This enzyme has a molecular mass of approximately 55 kDa and is mainly expressed in the liver with presence also noted in the kidney brain and other tissues. CYP7B1 catalyzes the hydroxylation of oxysterols and other sterol substrates which is an essential step in cholesterol homeostasis and metabolism. This enzyme functions within the endoplasmic reticulum using NADPH as a cofactor.
Biological function summary
CYP7B1 plays a role in the conversion of cholesterol derivatives into bile acids. It is not typically considered part of a larger protein complex but interacts locally with other enzymes for bile acid synthesis. The enzyme's activity ensures the maintenance of cholesterol balance by converting excess cholesterol into bile acids which are critical for fat digestion and absorption in the intestine. The products of CYP7B1 activity are further metabolized by other enzymes in the bile acid biosynthesis pathways contributing to lipid regulation in the body.
Pathways
CYP7B1 is integral to the alternative bile acid synthesis pathway distinguishing it from the classic pathway. This pathway provides a mechanism to balance cholesterol levels when the primary pathway is insufficient. CYP7B1 also relates functionally to CYP7A1 another enzyme involved in bile acid synthesis although CYP7A1 belongs to the classic pathway. These enzymes ensure that cholesterol conversion is adaptable and responsive to physiological needs maintaining lipid and energy homeostasis.
Mutations in CYP7B1 can lead to hereditary spastic paraplegia type 5 (SPG5) a neurological disorder characterized by progressive lower limb weakness and spasticity. The enzyme’s dysregulation also associates with liver conditions due to cholesterol and bile acid imbalance although the specifics of liver disease involvement remain under investigation. Associated pathways further implicate proteins like ABC transporters that manage lipid transport across membranes in both neurological and hepatic contexts connected to CYP7B1 dysfunction.